Triple

T16952532
Position Surface form Disambiguated ID Type / Status
Subject Daypro E411217 entity
Predicate mayInteractWith P3970 FINISHED
Object warfarin E241385 NE FINISHED

How this triple was built (2 steps)

Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.

NER Named-entity recognition gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: warfarin | Statement: [Daypro, mayInteractWith, warfarin]
NED1 Entity disambiguation (via context triple) gpt-5-mini-2025-08-07
Target entity: warfarin
Context triple: [Daypro, mayInteractWith, warfarin]
  • A. warfarin chosen
    Warfarin is a long-established oral anticoagulant used to prevent and treat blood clots, requiring regular blood monitoring and dose adjustments due to its narrow therapeutic range and numerous drug and food interactions.
  • B. dabigatran
    Dabigatran is an oral direct thrombin inhibitor anticoagulant used to prevent and treat blood clots and reduce the risk of stroke in patients with conditions like atrial fibrillation.
  • C. Xarelto
    Xarelto is a widely used prescription anticoagulant (blood thinner) that helps prevent and treat blood clots and reduce the risk of stroke in certain patients.
  • D. apixaban
    Apixaban is an oral anticoagulant (factor Xa inhibitor) used to prevent and treat blood clots and reduce the risk of stroke in patients with conditions such as atrial fibrillation.
  • E. DOAC
    DOAC (direct oral anticoagulant) is a class of blood-thinning medications that directly inhibit specific clotting factors to prevent and treat thromboembolic events.
  • F. None of above.
  • G. Unsure - the case is ambiguous/there is not enough information to decide.

Provenance (3 batches)

The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.

Step Stage Batch ID Status When
creating Elicitation batch_69d886c9c9d481909afe222093641cae completed April 10, 2026, 5:12 a.m.
NER Named-entity recognition batch_69e3d0197f308190af7185fc9cc7a6e9 completed April 18, 2026, 6:40 p.m.
NED1 Entity disambiguation (via context triple) batch_6a00d46213b08190b33b48d12bc795d1 completed May 10, 2026, 6:54 p.m.
Created at: April 10, 2026, 5:31 a.m.